Table 2.

Effects of RAR-γ Agonists on Cell Viability, Apoptosis, and Caspase Activation

Treatment No. Viable Cells ×1,000 (% viability)Apoptotic Index (%) DEVD-amc Hydrolytic Activity (Fluorescence Arbitrary Units)
Control  216 ± 27 1.5 ± 0.5  5.3 ± 0.2  
 (75 ± 2)  
CD437 128 ± 20* 66.8 ± 6.7 42.1 ± 2.3 
 (56 ± 10)  
CD2325  152 ± 18* 14.1 ± 1.4 18.0 ± 3.3 
 (56 ± 2)  
CD2781  212 ± 42 1.4 ± 0.6  6.9 ± 1.4  
 (68 ± 9) 
Treatment No. Viable Cells ×1,000 (% viability)Apoptotic Index (%) DEVD-amc Hydrolytic Activity (Fluorescence Arbitrary Units)
Control  216 ± 27 1.5 ± 0.5  5.3 ± 0.2  
 (75 ± 2)  
CD437 128 ± 20* 66.8 ± 6.7 42.1 ± 2.3 
 (56 ± 10)  
CD2325  152 ± 18* 14.1 ± 1.4 18.0 ± 3.3 
 (56 ± 2)  
CD2781  212 ± 42 1.4 ± 0.6  6.9 ± 1.4  
 (68 ± 9) 

Cells (200,000/mL) were treated with the indicated compounds for 16 hours. At the end of treatment, aliquots of the cultures were stained with erythrosin for the determination of the number of cells and their viability, and with DAPI for the determination of the number of apoptotic cells. Remaining cells were harvested, homogenized, and the extract was assayed for DEVD-amc hydrolytic activity. Each value represents the mean ± SD of three replicate cultures.

*

Statistically lower than control following the Student’st-test (P < .05).

Statistically higher than control following the Student’st-test (P < .01).

Close Modal

or Create an Account

Close Modal
Close Modal